EUCTR2011-005218-13-GB
Active, not recruiting
Phase 1
Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET - Optimisation of amisulpride prescribing in older people
Kings College London0 sites40 target enrollmentFebruary 28, 2012
ConditionsAlzheimer's Disease and schizophrenia likeillnessMedDRA version: 17.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852MedDRA version: 17.0Level: LLTClassification code 10032928Term: Other specified types of schizophreniaSystem Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Alzheimer's Disease and schizophrenia likeillness
- Sponsor
- Kings College London
- Enrollment
- 40
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy participants will be included if they
- •(i)are aged between 60 and 95 years of age
- •(ii)are male or female
- •(iii)score \<6 on the Geriatric depression scale (GDS)
- •(iv)score \>26/30 on the Mini Mental State Examination
- •Patients with SLP will be included if they
- •(i)meet diagnostic criteria for SLP (a non\-affective, non\-organic psychosis)
- •(ii)are aged between 60 and 95 years of age
- •(iii)are male or female
- •(iv)score \<6 on the Geriatric Depression Scale (GDS)
Exclusion Criteria
- •Healthy participants will be excluded for the following reasons:
- •(i)current or past psychiatric illness (such as schizophrenia), addiction (drug or alcohol), traumatic brain injury or epilepsy
- •(ii)prescribed psychotropic or other oral medication that might interfere with brain dopamine function in the past 2 weeks (6 weeks for depot medication).
- •(iii)medical conditions that might affect a person’s ability to tolerate a brain scan, such as significant respiratory or cardiac disease or severe kyphosis, or needle phobia (the latter because the scan required intravenous cannulation).
- •(iv)unable to give informed consent
- •Patients with SLP will be excluded for the following reasons
- •(i)past history of addiction (drug or alcohol), traumatic brain injury or epilepsy
- •(ii)prescribed an antipsychotic or other oral drug that interferes with brain dopamine function within the past 2 weeks (6 weeks for depot medication)\*
- •(iii)medical conditions that might affect a person’s ability to tolerate a brain scan, such as significant respiratory or cardiac disease or severe kyphosis, or needle phobia (the latter because the scan required intravenous cannulation).
- •(iv)unable to give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Phase 4
Optimisation of Antipsychotic Drug Use in Older PeopleAlzheimer's DiseaseSchizophreniaNCT01454453Institute of Psychiatry, London64
Terminated
Not Applicable
The relationship between quality of life , cognitive function and sedative medications that older people with dementia regularly consume.cognitive impairmentDementiaMental Health - Studies of normal psychology, cognitive function and behaviourNeurological - DementiasACTRN12620000393954Dementia Training Australia (WA)56
Recruiting
Not Applicable
Study of antipsychotic prescribing trends in a multi-modal care communication-educated healthcare facility.JPRN-UMIN000047400ational Hospital Organization Tokyo Medical Center1,600
Completed
Not Applicable
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.SchizophreniaSchizoaffective DisorderSchizophreniform DisorderDelusional DisorderPsychotic DisorderNCT00716755Centre for Addiction and Mental Health45
Recruiting
Not Applicable
Drug usage in geriatric patients visiting medicine outpatient departmentCTRI/2018/05/014159Pradeep G Jadhav